Alcon AG
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Endicott
- Full Time Employees
- 25,942
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Chemin de Blandonnet 8 Geneva GE Switzerland 1214
- IPO Date
- Apr 9, 2019
- Website
- alcon.com
- Similar Companies
- Business
- Alcon Inc. (ALC.SW) researches, develops, manufactures, distributes and sells eye care products worldwide, operating in two primary segments, Surgical and Vision Care; the Surgical segment provides equipment, instrumentation and diagnostics such as the Centurion vision system and LenSx laser system, intraocular lenses including PanOptix, Vivity and AcrySof IQ, other implantables, consumables like viscoelastics, surgical solutions, incisional instruments and custom packs for cataract, vitreoretinal and refractive surgeries; the Vision Care segment offers daily disposable, reusable and color-enhancing contact lenses under brands like Dailies, Total1, Precision1 and Air Optix, plus ocular health products including Systane dry eye drops, Pataday allergy relief, contact lens care solutions, ocular vitamins and redness relievers. Founded in 1945 in Fort Worth, Texas, by pharmacists Robert Alexander and William Conner, the company is incorporated in Fribourg, Switzerland, with global headquarters in Geneva and a major operational hub in Fort Worth; it employs over 25,000 associates, operates in 60 countries and serves patients in more than 140 countries. In recent developments, Alcon acquired a majority interest in Aurion Biotech in March 2025 to advance cell therapy AURN001 for corneal endothelial disease into Phase 3 trials, agreed to acquire LENSAR in March 2025 for its ALLY Robotic Cataract Laser System and Streamline software to bolster femtosecond laser-assisted cataract surgery, entered a definitive agreement in August 2025 to purchase STAAR Surgical for approximately $1.5 billion to add EVO implantable collamer lenses for myopia correction, and plans to acquire LumiThera for its photobiomodulation device targeting dry age-related macular degeneration, with most transactions expected to close in mid-to-late 2025.
Company News
Alcon Sees Another Bullish Rating After Clear Portfolio Growth Direction In Eyecare
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Algoma Central Corporation Announces $62.5 million Offering of 6.20% Convertible Unsecured Subordinated Debentures
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
Credo Expands AI Connectivity Portfolio With 1.6T ZeroFlap ALC
Credo Unveils 1.6T ZeroFlap Active Light Cable, Industry's First Row-Scale, Wide-Parallel Optical Interconnect for AI Data Centers
Algoma Central (TSE:ALC) Shares Cross Above 50 Day Moving Average – Here’s Why
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon: A Re-Rating In Eyesight
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
Alcon Prices EUR 500 Million Senior Notes Offering
Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy
Bill Ackman Just Disclosed 6 New Positions, and 4 of Them Are Financial Stocks. Here's What He's Betting On.
Why Netflix Stock Popped Today
Bill Ackman Buys Back Into Netflix Four Years After Selling at a Loss
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript
Alcon Stock Jumps 4% as Tariff Relief Lifts Profit Target
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs